<DOC>
	<DOCNO>NCT01111903</DOCNO>
	<brief_summary>Study two stage , sub-study .</brief_summary>
	<brief_title>A 2 Stage Trial Lenalidomide ( REV ) Asymptomatic Ovarian Cancer Patients With Increasing CA 125 Late Relapse</brief_title>
	<detailed_description>Stage A : To determine efficacy lenalidomide single agent patient recurrent ovarian cancer second third line . Stage B : To determine Maximum Tolerated Dose ( MTD ) lenalidomide combination chemotherapy consist carboplatin pegylated liposomal doxorubicin . Substudy : To investigate impact lenalidomide patient ' immune system affect cancer look immunize marker could predictive activity lenalidomide solid tumor .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Stage A : Patient : age &gt; 18 year . histological proven diagnosis epithelial cancer ovary , fallopian tube extraovarian papillary serous tumor . asymptomatic disease progression detect increase CA 125 level accord GCIG criterion systematic followup , without measurable lesion . disease progression &gt; 6 month first second line include platinum derivative . Patients receive previously taxane derivative . Adequate bone marrow , renal hepatic function define : . WBC &gt; 3.0 x 109/L Neutrophils ( ANC ) &gt; 1,5 x 109/L ; Platelets &gt; 100 x 109/L ; Hemoglobin &gt; 6 mmol/L ( 10,0 mg/dL ) ; Bilirubin &lt; 2 x upper normal limit normal range ; Estimated glomerular filtration rate &gt; 50 ml/mn accord CockroftGault formula . ECOG performance status = 0 1. life expectancy least 16 week give sign write informed consent participate trial fully understanding implication constraint protocol . Stage B : Patients age &gt; 18 year . histological proven diagnosis epithelial cancer ovary , fallopian tube extraovarian papillary serous tumor . disease progression &gt; 6 month first second line include platinum derivative . patient receive previously taxane derivative . Measurable disease RECIST evaluable disease GCIG ( CA125 ) . Patients include stage A disease progression lenalidomide could eligible phase B experience unacceptable toxicity lenalidomide stage A . Patients stop lenalidomide 7 day entry stage B ( 7 day wash ) . Adequate bone marrow , renal hepatic function define : . WBC &gt; 3.0 x 109/L Neutrophils ( ANC ) &gt; 1,5 x 109/L ; Platelets &gt; 100 x 109/L ; Hemoglobin &gt; 6 mmol/L ( 10,0 mg/dL ) ; Bilirubin &lt; 2 x upper normal limit normal range ; Estimated glomerular filtration rate &gt; 50 ml/mn accord CockroftGault formula . LVEF normal range ECOG performance status = 0 1. life expectancy least 16 week . give sign write informed consent participate trial fully understanding implication constraint protocol . Ovarian tumor low malignant potential ( borderline tumor ) . Nonepithelial ovarian mixed epithelial/non epithelial tumor ( e.g . mixed Mullerian tumor ) . Patients prior diagnosis malignancy cure surgery alone less 5 year study entry ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) . Patients receive previous radiotherapy . Presence symptomatic brain metastasis . Patients history seizure disorder central nervous system disorder ; preexist motor sensory neurologic pathology symptom &gt; NCICTC grade 1 . History congestive heart failure ( NYHA Classification &gt; 2 , even medically control . History clinical electrocardiographically document myocardial infarction within last 6 month . History atrial ventricular arrhythmia ( ≥ LOWN II ) . Thrombosis antithrombosis treatment within 6 month . History visceral bleeding , gastrointestinal ulcer 6 month . Obstructive subocclusive disease . Patients severe active infection . Concurrent severe medical problem unrelated malignancy would significantly limit full compliance study expose patient extreme risk decrease life expectancy . Fertile woman use adequate contraceptive method , pregnant breast feeding . Histories allergy sentimentality know similar chemical compound carboplatine , either doxorubicine liposomale pégylée , one constituent lenalidomide . Patient develop knotty erythema characterize rash desquamation grip ( take ) thalidomide medicine similaire . Previous administration lenalidomide . Seropositivity know virus human immunodeficiency ( HIV ) , pathology bind syndrome acquire immunodeficiency ( AIDS ) hepatitis activate type A , B C. Administration simultaneous chemotherapeutic drug , hormonal therapy , simultaneous radiotherapy study treatment period ( hormone replacement therapy allow steroid antiemetic ) . Dementia significantly alter mental status would prohibit understanding give informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>